Lung/Respiratory Conditions

Main Content

ALPINE 2

Study title

Randomized double blind phase 3b trial to evaluate the safety and efficacy of 2 treatment regimens of aztreonam 75 mg powder and solvent for nebulizer solution azetronam for inhalation solution (ALZI)

  • Principal Investigator: Dr. David Josey

Purpose

This study is evaluating an experimental drug in patients with cystic fibrosis and new onset respiratory tract Pseudomonas Aeruginosa infection.

Who can participate

Those eligible to participate in this study include:

  • Male or female ages 3 months to less than 18 years with cystic fibrosis and new onset respiratory tract Pseudomonas Aeruginosa infection

For more information

  • Cathy Hudgins
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson MS 39216
    (601) 815-9276
  • IRB Number: 2017-0246